MilliporeSigma Launches Genotoxic Screening, Expands Biodevelopment CentersBy
Part of the special news roundup of DCAT member companies for the DCAT Week ’17 Special Edition of DCAT Value Chain Insights (April 5, 2017)
MilliporeSigma, the life science business of Merck KGaA, recently launched a new genotoxicity screening service that boosts its capabilities in genotoxicity assessment and expanded its biodevelopment centers.
The new genotoxicity screening service, called CAN MultiFlow, is used to predict genotoxic and mode-of-action properties of substances, ingredients, and drug compounds.The new service is offered through MilliporeSigma’s BioReliance testing facilities based in Rockville, Maryland. The screening process uses flow cytometry to screen for clastogens, aneugens, and non-genotoxicants (CAN) in pharmaceutical compounds, agricultural chemicals, flavors, fragrances, and consumer products.The new assay is based on the MultiFlow kit from Litron Laboratories, a Rochester, New York-based supplier of flow cytometry kits.
The company also expanded its biodevelopment centers for its portfolio of bioprocessing products, manufacturing capabilities, and technological expertise. This expansion includes the opening of two new process development centers in Boston, Massachusetts and Shanghai, China and follows the commercial launch of MilliporeSigma’s biodevelopment center in Martillac, France. Each new center will provide a process-development capabilities and services, including cell-line development services, both upstream and downstream process development as well as non-GMP clinical production. MilliporeSigma’s biodevelopment center in Martillac, France, is a single-use, GMP facility for manufacturing clinical stage batches and is equipped with a 2,000 liter single-use bioreactor.